I. Background and Scope of the Investigation
On September 2, 2025, the U.S. Department of Commerce officially initiated a national security investigation into imported medical devices under Section 232 of the Trade Expansion Act. The investigation covers personal protective equipment (PPE), medical consumables, and critical medical devices, including products such as masks, syringes, and infusion pumps. The focus includes assessing U.S. domestic production capacity, dependence on foreign supply chains, and whether foreign subsidies constitute unfair competition to the U.S. supply chain. Although the investigation began in early September, it was not publicly announced via the Federal Register until September 24–25, causing industry upheaval.

This move follows the Trump administration's previous trade protection measures, such as imposing 50% tariffs on steel, aluminum, and copper, and 25% tariffs on auto parts, all justified under "national security." The U.S. Department of Commerce emphasized that if the investigation concludes that imported medical devices threaten national security, high tariffs may be imposed on relevant products to incentivize manufacturing回流 to the U.S.

II. Immediate Market Reactions and Industry Impact
Following the announcement, U.S. medical technology stocks fell collectively on September 25. GE HealthCare's stock dropped 3.35%, Becton Dickinson declined 2.93%, Intuitive Surgical fell 1.32%, and respiratory therapy device maker ResMed plunged 2.51%. Analysts noted that these companies heavily rely on global supply chains, with product assembly or raw material procurement often involving production outside the U.S.

Needham analyst Mike Matson stated that the investigation "adds new worries to an already struggling medical device sector." In the short term, companies may attempt to pass tariff costs onto hospitals or consumers. However, long-term policy pressures might force some companies to accelerate shifting production capacity to the U.S. Yet, this transition requires significant investment in time and capital, alongside challenges such as high local labor costs and insufficient supporting supply chains.

III. Global Supply Chain and Potential Risks for Chinese Companies
As one of the world's largest producers of medical devices, China could face direct impacts if the U.S. imposes tariffs. For instance, the U.S. has long relied on imports of masks, syringes, and similar products from China, with import values exceeding $10 billion in 2023. This investigation may compel U.S. buyers to seek alternative supply chains or accelerate production shifts to regions like Southeast Asia or Mexico.

Simultaneously, U.S. domestic medical device companies face dilemmas. For example, Boston Scientific, with a market cap of $145.3 billion and a 21.4% revenue growth over the past year, could see profit margins squeezed by rising costs from overseas production if tariffs are implemented. The company's recent plan to acquire Elutia's bio-envelope business for $88 million also reflects efforts to strengthen competitiveness through supply chain integration.

IV. Policy Developments and Industry Response Strategies
The Trump administration previously initiated Section 232 investigations on products like steel and aluminum, successfully imposing tariffs. The medical device investigation may follow a similar path. Procedurally, the U.S. Department of Commerce must submit a report to the President within 270 days. If national security risks are confirmed, Trump would have 90 days to decide whether to implement tariffs or other restrictions.

To mitigate potential impacts, some medical device companies have begun adjusting strategies. Examples include strengthening partnerships with U.S. domestic suppliers or investing in automated production lines to reduce labor costs. Additionally, some companies are lobbying the government for exemptions, similar to exception clauses for "products compliant with trade agreements or assembled in the U.S." under previous auto tariffs.